While the panel recognized that clinically significant prostate cancer (csPCa) can be MRI-invisible, there was no consensus as to the use of PSMA PET/CT as an adjunct to MRI for patient selection or in follow-up. Here, FOLH1 is linked to prostate carcinoma.